ETNB - 89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
2024-05-23 06:32:35 ET
Summary
- 89bio is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic conditions.
- Their drug candidate, pegozafermin, has shown positive results in reducing liver fat and insulin resistance and is in phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
- Pegozafermin has the potential to tap into a large market and has been granted FDA Breakthrough Therapy designation for treating MASH with fibrosis.
- Due to its metabolic regulation properties, pegozafermin's broader potential includes applications in Type 2 Diabetes, obesity, and other inflammatory diseases.
- I rate ETNB stock a “strong buy” due to Pegozafermin’s promising clinical data, substantial market potential, and robust financials.
...
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy